NCT05136391View on ClinicalTrials.gov

A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

August 27, 2021

Study Completion Date

August 27, 2021

Conditions
Coronary Artery Disease (CAD)
Interventions
DRUG

XTR003

Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.

Trial Locations (1)

100029

Beijing Anzhen Hospital, Beijing

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY

NCT05136391 - A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers | Biotech Hunter | Biotech Hunter